jRCT2080225287已完成3 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC)
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- MSD K.K.
- 入组人数
- 636
- 试验地点
- 1
- 主要终点
- BI-EFS
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Randomized Controlled Trial, Parallel Assignment, Multicenter Clinical Study, Double Blind
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Has a histologically confirmed initial diagnosis of MIBC with predominant urothelial histology (histology and presence of muscle invasion to be confirmed by blinded independent central review [BICR]) obtained via a diagnostic or maximal TURBT
- •Has clinically nonmetastatic bladder cancer (N0M0) determined by imaging and verified by BICR
- •Has planned and is eligible to receive CRT and one of the protocol-specified radiosensitizing chemotherapy regimens
- •Has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1, or 2
- •Demonstrates adequate organ function
- •Male participants are eligible to participate if they agree to use a method of birth control as detailed in the protocol during the intervention period and for at least 90 days after the last CRT treatment
- •A female participant is eligible to participate if she is not pregnant or breastfeeding, and if she agrees to use a method of birth control as detailed in the protocol and agrees not to donate eggs to others or freeze/store for her own use for the purpose of reproduction during the intervention period and for at least 180 days after the last CRT treatment/at least 120 days after the last dose of MK-3475
排除标准
- •Has the presence of diffuse carcinoma in situ (CIS) (multiple foci of CIS) throughout the bladder
- •Has the presence of urothelial carcinoma (UC) at any site outside of the urinary bladder in the previous 2 years
- •Has a known additional malignancy that is progressing or has required active therapy within the past 3 years
- •Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer or other carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) who have undergone potentially curative therapy are not excluded.
- •Has the presence of bilateral hydronephrosis during the Screening period
- •Has limited bladder function with frequency of small amounts of urine (<30 mL), urinary incontinence, or requires self-catheterization or a permanent indwelling catheter
- •Has received prior pelvic/local radiation therapy or any antineoplastic treatment for MIBC
- •Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137)
- •Has received a live vaccine within 30 days before the first dose of study medication
- •Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention
- •Has known severe hypersensitivity (>=Grade 3) to the selected chemotherapy regimen and/or any of their excipients and excipients of pembrolizumab
- •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the first dose of study medication
- •Has an active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs)
- •Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
- •Has an active infection requiring systemic therapy
- •Has a known history of human immunodeficiency virus (HIV) infection
- •Has a known history of hepatitis B (defined as HBsAg reactive) or known active hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection
- •Has a known history of active tuberculosis (TB; Bacillus tuberculosis)
- •Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
- •Has had an allogenic tissue/solid organ transplant
结局指标
主要结局
BI-EFS
时间窗: From randomization to first documented occurrence of any event
The time from randomization to the first documented occurrence of any of the following events: - Residual/recurrent MIBC (as assessed by cystoscopy, cytology, and biopsy results by central pathology review) - Nodal or distant metastases as assessed by CT of chest and CTU or MRU of the abdomen and pelvis per BICR and/or biopsy results assessed by central pathology review. If biopsy is not feasible due to participant safety, the imaging alone will be sufficient. - Radical cystectomy - Death from any cause
次要结局
- MFS
- Time to occurrence of NMIBC
- OS
- Number of participants with AE
- Number of participants discontinued due to AE
- Change from baseline in EORTC QLQ-C30 global health status/QoL
- Change from baseline in EORTC QLQ-C30 physical functioning
- Change from baseline in BCI domains
- Change from baseline in EQ-5D-5L VAS
- Time to deterioration in EORTC QLQ-C30 global health status/QoL
- Time to deterioration in EORTC QLQ-C30 physical functioning
- Time to deterioration in BCI domains
- Time to deterioration in EQ-5D-5L VAS
- Time from randomization to cystectomy
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Radiotherapy in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancerRecurrent prostate cancerC61Malignant neoplasm of prostateDRKS00025948niversitätsklinikum Freiburg49
进行中（未招募）
1 期
Evaluation of radiotherapy in combination with pembrolizumab in patients with recurrent prostate cancer after radical prostatectomyRecurrent prostate cancer - Patients with biochemical recurrence (BCR) or persisting prostate-specifiv antigen (PSA) after radical prostatectomy (RP)EUCTR2021-001291-42-DEniversitätsklinikum Freiburg49
进行中（未招募）
1 期
Phase II Trial of Pembrolizumab and Radiotherapy in Cutaneous T cell lymphomaCutaneous T cell lymphomaMedDRA version: 22.0Level: PTClassification code 10011677Term: Cutaneous T-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000433-30-GBniversity College London46
招募中
不适用
Phase II study of Pembrolizumab plus Chemotherapy With Lenvatinib for Malignant pleural mesothelioma (PENINSULA)Malignant pleural mesotheliomajRCT205123020925
进行中（未招募）
1 期
Phase 2 study of pembrolizumab and chemotherapy in participants with classical Hodgkin Lymphoma that has just been diagnosedClassical Hodgkin LymphomaMedDRA version: 20.1Level: LLTClassification code 10080208Term: Classical Hodgkin lymphomaSystem Organ Class: 100000004864EUCTR2021-001244-95-PLMerck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.140